ENLIVEN THERAPEUTICS, INC. Investing Cash Flow
ENLIVEN THERAPEUTICS, INC. (ELVN) reported Investing Cash Flow of -$399.04 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-05
- ENLIVEN THERAPEUTICS, INC. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was -$441.57M.
- ENLIVEN THERAPEUTICS, INC. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was $42.53M, a 2880.10% increase year-over-year.
- ENLIVEN THERAPEUTICS, INC. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was $12.38M, a 1602.75% increase year-over-year.
- ENLIVEN THERAPEUTICS, INC. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was -$4.06M, a 127.37% decline year-over-year.
- ENLIVEN THERAPEUTICS, INC. net cash provided by (used in) investing activities for fiscal 2025 was -$173.84M.
- ENLIVEN THERAPEUTICS, INC. net cash provided by (used in) investing activities for fiscal 2024 was -$36.00M.
- ENLIVEN THERAPEUTICS, INC. net cash provided by (used in) investing activities for fiscal 2023 was -$148.41M.
- ENLIVEN THERAPEUTICS, INC. net cash provided by (used in) investing activities for fiscal 2022 was -$612.00K.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 3 month as first filed | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 6 month as first filed | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 9 month as first filed | Net Cash Provided by (Used in) Investing Activities 12 month | Net Cash Provided by (Used in) Investing Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$441.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$399.04M 10-Q · filed 2026-08-05 | -$386.66M derived: sum of 3 quarters · filed 2026-08-05 | -$390.72M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | $42.53M 10-Q · filed 2026-05-07 | $54.91M derived: sum of 2 quarters · filed 2026-05-07 | $50.85M derived: sum of 3 quarters · filed 2026-05-07 | -$132.74M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $12.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $8.32M derived: sum of 2 quarters · filed 2026-03-03 | -$175.27M derived: sum of 3 quarters · filed 2026-08-05 | -$173.84M 10-K · filed 2026-03-03 | ||||
| 2025-09-30 | -$4.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$187.65M derived: sum of 2 quarters · filed 2026-08-05 | -$186.22M 10-Q · filed 2025-11-12 | -$185.49M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | -$183.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$182.16M 10-Q · filed 2026-08-05 | -$181.44M derived: sum of 3 quarters · filed 2026-08-05 | -$166.61M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | $1.43M 10-Q · filed 2026-05-07 | $2.15M derived: sum of 2 quarters · filed 2026-05-07 | $16.98M derived: sum of 3 quarters · filed 2026-05-07 | -$16.68M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | $727.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $15.55M derived: sum of 2 quarters · filed 2026-03-03 | -$18.11M derived: sum of 3 quarters · filed 2026-03-03 | -$36.00M 10-K · filed 2026-03-03 | ||||
| 2024-09-30 | $14.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$18.84M derived: sum of 2 quarters · filed 2025-11-12 | -$36.72M 10-Q · filed 2025-11-12 | $1.96M derived: sum of 4 quarters · filed 2025-11-12 | ||||
| 2024-06-30 | -$33.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$51.55M 10-Q · filed 2025-08-13 | -$12.86M derived: sum of 3 quarters · filed 2025-08-13 | -$48.41M derived: sum of 4 quarters · filed 2025-08-13 | ||||
| 2024-03-31 | -$17.89M 10-Q · filed 2025-05-14 | $20.80M derived: sum of 2 quarters · filed 2025-05-14 | -$14.75M derived: sum of 3 quarters · filed 2025-05-14 | -$166.27M derived: sum of 4 quarters · filed 2025-05-14 | ||||
| 2023-12-31 | $38.69M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $3.14M derived: sum of 2 quarters · filed 2025-03-13 | -$148.38M derived: sum of 3 quarters · filed 2025-03-13 | -$148.41M 10-K · filed 2025-03-13 | ||||
| 2023-09-30 | -$35.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$187.07M derived: sum of 2 quarters · filed 2024-11-13 | -$187.10M 10-Q · filed 2024-11-13 | -$187.20M derived: sum of 4 quarters · filed 2024-11-13 | ||||
| 2023-06-30 | -$151.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$151.55M 10-Q · filed 2024-08-13 | -$151.65M derived: sum of 3 quarters · filed 2024-08-13 | -$151.66M derived: sum of 4 quarters · filed 2024-08-13 | ||||
| 2023-03-31 | -$31.00K 10-Q · filed 2024-05-14 | -$132.00K derived: sum of 2 quarters · filed 2024-05-14 | -$146.00K derived: sum of 3 quarters · filed 2024-05-14 | -$449.00K derived: sum of 4 quarters · filed 2024-05-14 | ||||
| 2022-12-31 | -$101.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | -$115.00K derived: sum of 2 quarters · filed 2024-03-14 | -$418.00K derived: sum of 3 quarters · filed 2024-03-14 | -$612.00K 10-K · filed 2024-03-14 | $76.52M 10-K · filed 2023-02-10 | |||
| 2022-09-30 | -$14.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$317.00K derived: sum of 2 quarters · filed 2023-11-09 | -$511.00K 10-Q · filed 2023-11-09 | $34.70M 10-Q · filed 2022-10-25 | -$13.56M derived: sum of 4 quarters · filed 2023-11-09 | |||
| 2022-06-30 | -$303.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$497.00K 10-Q · filed 2023-08-10 | $11.61M 10-Q · filed 2022-08-03 | -$13.55M derived: sum of 3 quarters · filed 2023-08-10 | -$22.38M derived: sum of 4 quarters · filed 2023-08-10 | |||
| 2022-03-31 | -$194.00K 10-Q · filed 2023-05-11 | $5.33M 10-Q · filed 2022-05-06 | -$13.24M derived: sum of 2 quarters · filed 2023-06-23 | -$22.08M derived: sum of 3 quarters · filed 2023-06-23 | -$18.69M derived: sum of 4 quarters · filed 2023-06-23 | |||
| 2021-12-31 | -$13.05M derived: 8-K 12 month − 10-Q 9 month · filed 2023-06-23 | -$21.88M derived: sum of 2 quarters · filed 2023-06-23 | -$18.49M derived: sum of 3 quarters · filed 2023-06-23 | -$191.00K 8-K · filed 2023-06-23 | -$1.63M 10-K · filed 2022-03-15 | |||
| 2021-09-30 | -$8.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-25 | -$5.44M derived: sum of 2 quarters · filed 2022-10-25 | $12.86M 10-Q · filed 2022-10-25 | $34.07M derived: sum of 4 quarters · filed 2022-10-25 | ||||
| 2021-06-30 | $3.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $21.69M 10-Q · filed 2022-08-03 | $42.90M derived: sum of 3 quarters · filed 2022-08-03 | $32.62M derived: sum of 4 quarters · filed 2022-08-03 | ||||
| 2021-03-31 | $18.30M 10-Q · filed 2022-05-06 | $39.52M derived: sum of 2 quarters · filed 2022-05-06 | $29.23M derived: sum of 3 quarters · filed 2022-05-06 | -$3.17M derived: sum of 4 quarters · filed 2022-05-06 | ||||
| 2020-12-31 | $21.21M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $10.93M derived: sum of 2 quarters · filed 2022-03-15 | -$21.48M derived: sum of 3 quarters · filed 2022-03-15 | -$16.72M 10-K · filed 2022-03-15 | ||||
| 2020-09-30 | -$10.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | -$42.69M derived: sum of 2 quarters · filed 2021-11-09 | -$37.93M 10-Q · filed 2021-11-09 | -$40.05M derived: sum of 4 quarters · filed 2021-11-09 | ||||
| 2020-06-30 | -$32.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | -$27.65M 10-Q · filed 2021-08-06 | -$29.76M derived: sum of 3 quarters · filed 2021-08-06 | -$51.63M derived: sum of 4 quarters · filed 2021-08-06 | ||||
| 2020-03-31 | $4.76M 10-Q · filed 2021-05-11 | $2.65M derived: sum of 2 quarters · filed 2021-05-11 | -$19.22M derived: sum of 3 quarters · filed 2021-05-11 | |||||
| 2019-12-31 | -$2.11M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-05 | -$23.98M derived: sum of 2 quarters · filed 2021-03-05 | -$24.06M 10-K · filed 2021-03-05 | |||||
| 2019-09-30 | -$21.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$21.95M 10-Q · filed 2020-11-05 | ||||||
| 2019-06-30 | -$81.00K 10-Q · filed 2020-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |